Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
1AD | Ann: SYNThesis BioVentures MoU for cellular immunotherapies | 24/04/24 | 122 | 21K | |||
|
|||||||
1AD | Ann: Notification of Expiry of Listed Options | 24/04/24 | 6 | 722 | |||
|
|||||||
1AD | Ann: SYNBV MoU Webinar presentation | 16/04/24 | 88 | 14K | |||
|
|||||||
1AD | News: 1AD Adalta Says Co & Synthesis Bioventures Partner For Development Of Next Generation... | 08/04/24 | 0 | 146 | |||
|
|||||||
1AD | Ann: Webinar to discuss SYNthesis BioVentures partnership | 08/04/24 | 0 | 285 | |||
|
|||||||
1AD | Ann: Positive AD-214 Phase I extension study results | 05/04/24 | 262 | 47K | |||
|
|||||||
1AD | Ann: January 2024 partnering presentations and progress | 04/04/24 | 22 | 5.2K | |||
|
|||||||
1AD | Ann: 1AD & GPCR Therapeutics to evaluate CXCR4 i-bodies in cancer | 29/03/24 | 10 | 3.2K | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |